Difference between revisions of "Momelotinib (Ojjaara)"
Jump to navigation
Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
m (→Myelofibrosis) |
||
Line 5: | Line 5: | ||
===[[Myelofibrosis]]=== | ===[[Myelofibrosis]]=== | ||
# Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, Litzow MR, Leontovich A, Kowalski M, Tefferi A. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013 Jun;27(6):1322-7. Epub 2013 Mar 5. [https://www.ncbi.nlm.nih.gov/pubmed/23459451 PubMed] | # Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, Litzow MR, Leontovich A, Kowalski M, Tefferi A. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013 Jun;27(6):1322-7. Epub 2013 Mar 5. [https://www.ncbi.nlm.nih.gov/pubmed/23459451 PubMed] | ||
+ | # '''SIMPLIFY-1:''' Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol. 2017 Dec 1;35(34):3844-3850. Epub 2017 Sep 20. [http://ascopubs.org/doi/full/10.1200/JCO.2017.73.4418 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28930494 PubMed] | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
− | [[Category: | + | [[Category:Oral medications]] |
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] |
Revision as of 21:28, 8 March 2018
Mechanism of action
JAK1/2 inhibitor
Preliminary data
Myelofibrosis
- Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, Litzow MR, Leontovich A, Kowalski M, Tefferi A. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013 Jun;27(6):1322-7. Epub 2013 Mar 5. PubMed
- SIMPLIFY-1: Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol. 2017 Dec 1;35(34):3844-3850. Epub 2017 Sep 20. link to original article PubMed